Alpha 2.0
Login Register
» Authors » Tatjana Pandzic

Tatjana Pandzic

Explore the profile of Tatjana Pandzic including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 331
Followers 0
Related Specialties
Hematology
Oncology
Biochemistry
Top 10 Co-Authors
Viktor Ljungstrom
Lucia Cavelier
Panagiotis Baliakas
Richard Rosenquist
Tobias Sjoblom
Kostas Stamatopoulos
Paolo Ghia
Larry Mansouri
Liqun He
Lesley-Ann Sutton
Published In
Oncotarget
Leuk Lymphoma
Blood
Am J Hematol
Br J Haematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Cancer associated variant enrichment CAVE, a gene agnostic approach to identify low burden variants in chronic lymphocytic leukemia
Yaacov A, Lazarian G, Pandzic T, Westrom S, Baliakas P, Imache S, et al.
Sci Rep . 2024 Sep; 14(1):21962. PMID: 39304718
Intratumoral heterogeneity is an important clinical challenge because low burden clones expressing specific genetic alterations drive therapeutic resistance mechanisms. We have developed CAVE (cancer-associated variant enrichment), a gene-agnostic computational tool...
2.
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing
Thangavelu T, Wirta V, Orsmark-Pietras C, Cavelier L, Fioretos T, Barbany G, et al.
J Med Econ . 2024 Aug; 27(1):1053-1060. PMID: 39101813
Aims And Background: Whole-genome sequencing (WGS) is increasingly applied in clinical practice and expected to replace standard-of-care (SoC) genetic diagnostics in hematological malignancies. This study aims to assess and compare...
3.
Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture-Based Gene Panel
Orsmark-Pietras C, Lyander A, Ladenvall C, Hallstrom B, Staffas A, Awier H, et al.
Genes Chromosomes Cancer . 2024 Jul; 63(7):e23257. PMID: 39031442
Gene panel sequencing has become a common diagnostic tool for detecting somatically acquired mutations in myeloid neoplasms. However, many panels have restricted content, provide insufficient sensitivity levels, or lack clinically...
4.
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Tobiasson M, Pandzic T, Illman J, Nilsson L, Westrom S, Ejerblad E, et al.
J Clin Oncol . 2024 Jan; 42(12):1378-1390. PMID: 38232336
Purpose: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and...
5.
Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML
Nyquist O, Dalgaard J, Spetalen S, Torkildsen S, Froen H, Galteland E, et al.
Br J Haematol . 2023 Nov; 204(2):724-729. PMID: 38016923
No abstract available.
6.
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
Bonfiglio S, Sutton L, Ljungstrom V, Capasso A, Pandzic T, Westrom S, et al.
Blood Adv . 2023 Jan; 7(12):2794-2806. PMID: 36696464
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance...
7.
Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting
Pandzic T, Ladenvall C, Engvall M, Mattsson M, Hermanson M, Cavelier L, et al.
Hemasphere . 2022 Aug; 6(8):e761. PMID: 35935605
The clinical significance of small clones detected with next generation sequencing (NGS) in chronic lymphocytic leukemia is an issue of active debate. According to the official guidelines, treatment decisions should...
8.
Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
Chen L, Eriksson A, Westrom S, Pandzic T, Lehmann S, Cavelier L, et al.
Nat Commun . 2022 Jul; 13(1):4033. PMID: 35821208
Rare tumor-specific mutations in patient samples serve as excellent markers to monitor the course of malignant disease and responses to therapy in clinical routine, and improved assay techniques are needed...
9.
Familial platelet disorder due to germline exonic deletions in : a diagnostic challenge with distinct alterations of the transcript isoform equilibrium
Engvall M, Karlsson Y, Kuchinskaya E, Jornegren A, Mathot L, Pandzic T, et al.
Leuk Lymphoma . 2022 May; 63(10):2311-2320. PMID: 35533071
Germline pathogenic variants in are associated with familial platelet disorder with predisposition to myeloid malignancies (FPD/MM) with intragenic deletions in accounting for almost 7% of all reported variants. We present...
10.
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy
Voso M, Pandzic T, Falconi G, Dencic-Fekete M, De Bellis E, Scarfo L, et al.
Br J Haematol . 2022 Mar; 198(1):103-113. PMID: 35277855
Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we...